Balyasny Asset Management
FLNA

Balyasny Asset Management’s Filana Therapeutics FLNA Stock Holding History

Balyasny Asset Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-42,099
Closed -$948K – 3063
2023
Q4 		$948K Sell
42,099
-107,789
-72% -$2.28M ﹤0.01% 1714
2023
Q3 		$2.49M Buy
149,888
+119,169
+388% +$2.36M 0.01% 1320
2023
Q2 		$753K Buy
30,719
+21,326
+227% +$514K ﹤0.01% 1730
2023
Q1 		$227K Buy
+9,393
New +$260K ﹤0.01% 2194
2022
Q4 		– Sell
-6,783
Closed -$283K – 3182
2022
Q3 		$283K Buy
+6,783
New +$183K ﹤0.01% 2216
2015
Q3 		– Sell
-1,536
Closed -$19K – 1350
2015
Q2 		$19K Buy
+1,536
New +$21K ﹤0.01% 1118

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Balyasny Asset Management's FLNA Position: Q1 2024 in Review

Balyasny Asset Management sold out of Filana Therapeutics (FLNA) in Q1 2024, closing a stake of 42,099 shares — an estimated $948K sold.

Balyasny Asset Management first reported a position in FLNA in Q2 2015 and held it in 6 quarters. The position peaked at $2.49M in Q3 2023. 143 funds tracked by Wall St. Rank hold FLNA as of Q1 2024.

  • Balyasny Asset Management reported no remaining Filana Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 42,099 Filana Therapeutics shares in Q1 2024, an estimated $948K.
  • Balyasny Asset Management first reported a position in Filana Therapeutics in Q2 2015 and held it in 6 quarters.
  • Balyasny Asset Management's Filana Therapeutics position peaked at $2.49M in Q3 2023.
  • 143 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.